Efficacy studies

Juan Pedro-Botet, Juana A. Flores-Le Roux

Research output: Contribution to journalArticleResearchpeer-review


Pravafenix® is a fixed-dose combination of 40mg of pravastatin and 160mg of fenofibrate. The rationale behind the use of Pravafenix® is based on the increased residual cardiovascular risk observed in high risk patients with hypertriglyceridemia and/or low HDL cholesterol levels despite treatment with statins in monotherapy. In this article, we review the available evidence on the clinical efficacy of Pravafenix®, which shows complementary benefits in the overall lipid profile of high risk patients with mixed dyslipidemia not controlled with 40-mg pravastatin or 20-mg simvastatin. © 2014 Sociedad Española de Arteriosclerosis Elsevier España, S.L.
Original languageEnglish
Pages (from-to)17-19
JournalClinica e Investigacion en Arteriosclerosis
Issue numberSUPP.1
Publication statusPublished - 1 Jan 2014


  • Atherogenic dyslipidemia
  • Clinical efficacy
  • Non-HDL cholesterol
  • Residual cardiovascular risk


Dive into the research topics of 'Efficacy studies'. Together they form a unique fingerprint.

Cite this